Project Grant W81XWH2210869

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) totaling $673,379 will support the development of a novel synthetic biology-based cellular immunotherapy for treating ulcerative colitis. The primary awardee, Rise Therapeutics LLC, is advancing their lead candidate R-3750, an engineered Lactococcus lactis strain that expresses the anti-inflammatory surface layer protein A...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $604,082 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Duke University to assess the use of psyllium fiber given with meals for managing fructan sensitivity in children with irritable bowel syndrome (IBS). The key objectives of this 3-year project are to: 1) investigate the effect of two different psyllium doses on microbial fructan fermentation...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a platform delivery system for targeted oral delivery of therapeutic proteins (biologics) to the intestines. Specifically, the $698,074 grant will support the formulation of recombinant human Proteoglycan 4 (rhPRG4) to protect it from degradation in the gastrointestinal...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $919,404 to Qrono, Inc. to develop QR401, a first-in-class oral nanomedicine targeting antigen-presenting cells (APCs) for the treatment of inflammatory bowel disease (IBD). The goal is to leverage the AMPK pathway to restore immune tolerance and alleviate intestinal...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,255,725 to the Icahn School of Medicine at Mount Sinai to advance the development and manufacture of defined live microbial therapeutics for the treatment of infectious and inflammatory diseases. The key objectives of this 4-year project are to: 1) Develop a solid-state fermentation...

This $325,139 federal Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS), 93.350 program, aims to examine the feasibility of using target-specific polyclonal antibodies to neutralize bioactive molecules in the gut microbiome. The primary goals are to 1) determine the impact of six proteins identified as overabundant in inflammatory gut disorders, and 2) evaluate the ability of immunoglobulin Y (IgY) antibodies to neutralize the physiological impacts...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $584,750 to Foli Bio Inc. to validate the functional utility of their EXFO-SEQ technology. EXFO-SEQ is an innovative platform that enables the precise and robust quantification of host gene expression directly from stool samples, providing a non-invasive means to longitudinally profile...

This Project Grant award, with ID R01AT013241, was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The $2,279,811 award aims to develop and utilize novel activity-based probes (ABPs) to directly characterize enzymatic function and microbial mechanisms within the gut microbiome, particularly in the context of inflammatory bowel disease (IBD). The primary research activities involve synthesizing ABPs targeting...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $817,161 to investigate the use of mesenchymal stem cells (MSCs) derived from the human gut as a novel autologous cell therapy for treating perianal fistulas, a serious complication of Crohn's disease. The 3-year research project, led by Mercer University in Macon, Georgia, aims to characterize the potency and...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding the development of a novel class of oral drugs that inhibit the migration of activated T cells to the gut. The $1,078,081 award to Orphagen Pharmaceuticals, Inc. aims to advance a lead antagonist compound, OR-812, that has demonstrated the ability to block the induction of...